Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Innovation ETF (ARKK) vs Mesoblast Limited (MESO) Price & Performance

ARK Innovation ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

ARK Innovation ETF vs Mesoblast Limited — how do they compare? ARK Innovation ETF trades at $81.26, while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: ARK Innovation ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

ARKKMESO
52-Week High
$92.50$20.96
52-Week Low
$63.52$12.88
Market Cap
$2.16B
Sector
Technology
Enterprise Value
$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Innovation ETF

ARK Innovation ETF (ARKK) trades at $79.43, up 4.89% today with strong technical momentum as moving averages signal bullish alignment. The ETF faces mixed sentiment with recent Seeking Alpha articles highlighting concentration risks in SpaceX and Tesla holdings while Cathie Wood continues aggressive AI stock purchases. Technical indicators show RSI at overbought levels near 82, suggesting potential near-term consolidation despite the bullish trend.

Outlook remains polarized between innovation optimism and valuation concerns. The fund's heavy exposure to speculative tech names offers growth potential but carries significant volatility risk. Recent underperformance versus broad market indices and high fee structure present headwinds, while continued institutional interest in disruptive technologies provides long-term catalysts.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About ARK Innovation ETF

The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.

Read more on ARKK

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO